source
- AriBio’s oral Alzheimer’s drug meets monotherapy goal in phase 3 as Fosun weighs licensing optionAriBio’s erectile dysfunction med-turned Alzheimer’s disease candidate mirodenafil has delivered some mixed results from a global phase 3 trial. Fosun Pharma has an option to in-license the PDE5 in…Fierce Biotech · 15h ago↗ source
- FDA denies Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer, halting US entryThe U.S. Food and Drug Administration issued a complete response letter rejecting Summit Therapeutics' biologics license application for ivonescimab, a PD-1xVEGF bispecific antibody intended for EG…